Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis

D. H. Miller, P. Rudge, G. Johnson, B. E. Kendall, D. G. MacManus, I. F. Moseley, D. Barnes, W. I. McDonald

Research output: Contribution to journalArticlepeer-review

377 Citations (Scopus)


Serial gadolinium-DTPA (Gd-DTPA) enhanced magnetic resonance imaging (MRI) was performed in 9 patients with multiple sclerosis (MS). On the first scan enhancing lesions were seen in 7 patients, all of whom were in acute relapse. Most enhancing lesions were asymptomatic. On the second scan (3 to 5 weeks later), persisting enhancement was seen in only 12/54 lesions which enhanced on the first scan. No lesion showed persisting enhancement on the third scan (after 6 months). Enhancement occurred in all 12 new lesion areas seen on the unenhanced second scan and in 8 of 15 new lesions seen on the third scan. Enhancement was also seen in 4 older lesions which had been nonenhancing on earlier scans. Relaxation time measurements demonstrated a high water content in some nonenhancing lesions, which could be due to a subtle blood-brain barrier disturbance not detected with Gd-DTPA. The results show that blood-brain barrier impairment is a consistent finding in new MS lesions detected with MRI. Gd-DTPA is a useful marker of new and biologically active lesions and should prove of value in monitoring therapeutic trials in MS.
Original languageEnglish
Pages (from-to)927-939
Number of pages13
Issue number4
Publication statusPublished - Aug 1988


  • Adult
  • Blood-Brain Barrier
  • Brain Pathology
  • Gadolinium DTPA
  • Humans
  • Magnetic Resonance Imaging
  • Middle Aged
  • Multiple Sclerosis Pathology
  • Organometallic Compounds Adverse Effects
  • Organometallic Compounds Diagnostic Use
  • Pentetic Acid Adverse Effects
  • Pentetic Acid Diagnostic Use
  • Spinal Cord Pathology
  • Time Factors

Cite this